UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer

A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2–73.3%), and the median progression-free survival was 8.8 months. There were no gra...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrioli, R, Sabatino, M, Fiaschi, A I, Marsili, S, Pozzessere, D, Messinese, S, Correale, P, Civitelli, S, Tanzini, G, Tani, F, De Martino, A, Marzocca, G, Lorenzi, M, Giorgi, G, Francini, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409570/
https://www.ncbi.nlm.nih.gov/pubmed/14735168
http://dx.doi.org/10.1038/sj.bjc.6601521
_version_ 1782155800643371008
author Petrioli, R
Sabatino, M
Fiaschi, A I
Marsili, S
Pozzessere, D
Messinese, S
Correale, P
Civitelli, S
Tanzini, G
Tani, F
De Martino, A
Marzocca, G
Lorenzi, M
Giorgi, G
Francini, G
author_facet Petrioli, R
Sabatino, M
Fiaschi, A I
Marsili, S
Pozzessere, D
Messinese, S
Correale, P
Civitelli, S
Tanzini, G
Tani, F
De Martino, A
Marzocca, G
Lorenzi, M
Giorgi, G
Francini, G
author_sort Petrioli, R
collection PubMed
description A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2–73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand–foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.
format Text
id pubmed-2409570
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24095702009-09-10 UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer Petrioli, R Sabatino, M Fiaschi, A I Marsili, S Pozzessere, D Messinese, S Correale, P Civitelli, S Tanzini, G Tani, F De Martino, A Marzocca, G Lorenzi, M Giorgi, G Francini, G Br J Cancer Short Communication A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2–73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand–foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC. Nature Publishing Group 2004-01-26 2004-01-20 /pmc/articles/PMC2409570/ /pubmed/14735168 http://dx.doi.org/10.1038/sj.bjc.6601521 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Petrioli, R
Sabatino, M
Fiaschi, A I
Marsili, S
Pozzessere, D
Messinese, S
Correale, P
Civitelli, S
Tanzini, G
Tani, F
De Martino, A
Marzocca, G
Lorenzi, M
Giorgi, G
Francini, G
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
title UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
title_full UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
title_fullStr UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
title_full_unstemmed UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
title_short UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
title_sort uft/leucovorin and oxaliplatin alternated with uft/leucovorin and irinotecan in metastatic colorectal cancer
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409570/
https://www.ncbi.nlm.nih.gov/pubmed/14735168
http://dx.doi.org/10.1038/sj.bjc.6601521
work_keys_str_mv AT petriolir uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT sabatinom uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT fiaschiai uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT marsilis uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT pozzessered uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT messineses uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT correalep uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT civitellis uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT tanzinig uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT tanif uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT demartinoa uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT marzoccag uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT lorenzim uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT giorgig uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer
AT francinig uftleucovorinandoxaliplatinalternatedwithuftleucovorinandirinotecaninmetastaticcolorectalcancer

Ejemplares similares